Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on the administration of the companies’ COVID-19 vaccine as a booster dose at least six months after the second dose in individuals 18 years of age and older.
Pfizer and BioNTech receive CHMP positive opinion for COVID-19 vaccine booster in the European Union
October 4, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022